Friday, 15 Nov 2019

You are here

Changing Patterns of Drug Use in Pregnant Rheumatic Patients: Steroids Down, Biologics Up

Desai and coworkers analyzed public and private insurance claims data (2001-2012) to assess patterns of drug use in pregnant woment with RA, SLE, PsA and AS. Specifically, they looked at immunosuppressive drug use in the 3 months preceding and during pregnancy.

A total of 2,645 women actively treated with immunomodulatory agents prior to pregnancy were included. More women with PsA or AS stopped these immunomodulatory prescriptions upon becoming pregnant (61%) compared with women diagnosed with SLE (26%) or RA (34.5%). From the first to the third trimester, the proportion of women filling prescriptions for immunomodulatory agents decreased across all indications.

Overall, steroids (48.4%) and hydroxychloroquine (27.1%) were the most frequently used agents in pregnancy. Steroid prescription refills during pregnancy fell significantly from 54.4 to 42.4; rates for biologics increased from 5.1 to 16.6 between 2001 and 2012 (p<0.001).

While steroids and hydroxychloroquine remain the most widely prescribed treatments during pregnancy, biologic use is increasing in recent years. Presumably this reflects the increasing reports of TNF inhibitor safety in pregnant women.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Rheumatologists' Comments

I'd like to keep reading, but the link on the continue reading button is incorrect. Please help!
Thank you for bringing this to our attention - it's been corrected, and you can now access the correct link. -- Tammy J. Tilley, editor

More Like This

Mallinckrodt Receives SEC Subpoena

Reuters reports that Mallinckrodt Plc has received a subpoena from the U.S. Securities and Exchange Commission for documents related to the drugmaker’s lawsuit against the U.S. Department of Health and Human Services (HHS).

ACR Responds to CY2020 Medicare Physician Fee Schedule Proposed Rule

Rheumatology leaders commend CMS for proposing E/M code changes and urge agency to make additional changes to final rule.d

Parenteral Out-Performs Oral Weekly Methotrexate

A systematic review in PLOS suggests that parenteral MTX therapy is more successful than oral MTX in achieving optimal disease activity control. 

ACR Survey Shows Half of Patients Cannot Afford Treatments

Americans living with rheumatic disease face significant healthcare challenges, according to a national patient survey released this week by the American College of Rheumatology. More than 1,500 U.S. adults living with rheumatic disease responded to the survey, which asked a range of questions related to healthcare access, affordability and lifestyle. Key findings include that even though 90 percent of respondents reported having health insurance coverage, nearly 60 percent said they had difficulty affording their medications or treatments in the past year.

Medical Use of Cannabis in 2019

JAMA has published an overview of cannabis and its medical uses. Although nearly 10% of cannabis users in the United States report using it for medicinal purposes, there is insufficient evidence to support the use of medical cannabis for most conditions for which its use is advocated or advised. Nevertheless, there is increase in favoring the public availability of cannabis, largely for the management of more than 50 medical conditions.